KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GoodRx Holdings (GDRX) Receivables (2019 - 2025)

Historic Receivables for GoodRx Holdings (GDRX) over the last 7 years, with Q3 2025 value amounting to $203.7 million.

  • GoodRx Holdings' Receivables rose 5575.94% to $203.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $203.7 million, marking a year-over-year increase of 5575.94%. This contributed to the annual value of $145.9 million for FY2024, which is 161.97% up from last year.
  • According to the latest figures from Q3 2025, GoodRx Holdings' Receivables is $203.7 million, which was up 5575.94% from $189.0 million recorded in Q2 2025.
  • GoodRx Holdings' Receivables' 5-year high stood at $203.7 million during Q3 2025, with a 5-year trough of $74.4 million in Q1 2021.
  • Moreover, its 5-year median value for Receivables was $123.3 million (2022), whereas its average is $131.7 million.
  • As far as peak fluctuations go, GoodRx Holdings' Receivables skyrocketed by 6570.25% in 2022, and later plummeted by 554.75% in 2023.
  • Quarter analysis of 5 years shows GoodRx Holdings' Receivables stood at $118.1 million in 2021, then fell by 0.8% to $117.1 million in 2022, then increased by 22.59% to $143.6 million in 2023, then rose by 1.62% to $145.9 million in 2024, then soared by 39.61% to $203.7 million in 2025.
  • Its Receivables was $203.7 million in Q3 2025, compared to $189.0 million in Q2 2025 and $160.1 million in Q1 2025.